The Center for Disease Control (CDC) estimates that about 1 in 12 people (about 25 million) have asthma, and the numbers are increasing every year. Studies show that approximately 5-10% of asthmatics (1.25-2.5 million people) have Aspirin Exacerbated Respiratory Disease (AERD) formerly referred to as Samter’s triad. AERD is a chronic respiratory condition which includes asthma, chronic inflammatory sinus disease, nasal polyps and an adverse reaction to Aspirin and Non-steroidal Anti-Inflammatory Drugs.  Approximately 40% of asthmatics with nasal polyps have AERD.

As a result, in 2004 Nyack Hospital and John Bosso, M.D., Chief of Allergy and Immunology at Nyack Hospital and graduate of the allergy/immunology fellowship at Scripps Clinic (where the procedure was initiated and perfected) created a new Aspirin-Desensitization Program. The first of its kind on the East Coast, this program involves giving patients increasing doses of Aspirin to deter their body’s reactions to the medication in a controlled medical setting.

Since its inception, the program has grown dramatically and Dr Bosso has successfully desensitized over 600 patients with AERD; as a result our program is the busiest in the Eastern United States.  Benefits of taking Aspirin after the desensitization procedure include: decreased nasal congestion, fewer nasal polyps, less sinus infections and asthma symptoms, reductions in the need for prednisone and sinus surgery procedures. In addition, most patients have an improvement in their sense of smell and overall quality of life.

For more information about aspirin desensitization and to set up a consultation, please call 845.353.9600.